Skip to main content
Top
Published in: Rheumatology International 11/2008

01-09-2008 | Original Article

Systemic reduction of soluble complement receptor II/CD21 during pregnancy to levels reminiscent of autoimmune disease

Authors: Madhan Masilamani, Narendiran Rajasekaran, Anjana Singh, Hui-Zhi Low, Kerstin Albus, Swantje Anders, Frank Behne, Peter Eiermann, Katharina König, Clarissa Mindnich, Teodora Ribarska, Harald Illges

Published in: Rheumatology International | Issue 11/2008

Login to get access

Abstract

Complement receptor type II/CD21 is the functional receptor for complement fragments such as C3d, iC3b and the Epstein Barr Virus. A soluble form of CD21 (sCD21) is shed from lymphocytes surface and is able to bind to its ligands found in the plasma. The amount of sCD21 in serum may modulate immunity as the plasma levels are correlated with autoimmune conditions, such as Systemic Lupus Erythematosus, Rheumatoid Arthritis and Sjoegren’s Syndrome. Because of the fact that pregnancy may lead to remission of autoimmune diseases we determined the serum levels of sCD21 during pregnancy and postpartum. The serum sCD21 levels during pregnancy are significantly lower as compared to that of the healthy controls. There were no significant differences in sCD21 levels between the mother and the cord blood also immediately after parturition. Restoration of sCD21 levels to normal values takes between 6 weeks and 1 year after childbirth. Our study indicates that CD21-shedding is affected during pregnancy comparable to that of autoimmunity.
Literature
1.
go back to reference Myones BL, Ross GD (1987) Identification of a spontaneously shed fragment of B cell complement receptor type two (CR2) containing the C3d-binding site. Complement 4:87–98PubMed Myones BL, Ross GD (1987) Identification of a spontaneously shed fragment of B cell complement receptor type two (CR2) containing the C3d-binding site. Complement 4:87–98PubMed
2.
go back to reference Ling N, Hansel T, Richardson P, Brown B (1991) Cellular origins of serum complement receptor type 2 in normal individuals and in hypogammaglobulinaemia. Clin Exp Immunol 84:16–22PubMed Ling N, Hansel T, Richardson P, Brown B (1991) Cellular origins of serum complement receptor type 2 in normal individuals and in hypogammaglobulinaemia. Clin Exp Immunol 84:16–22PubMed
3.
go back to reference Huemer HP, Larcher C, Prodinger WM, Petzer AL, Mitterer M, Falser N (1993) Determination of soluble CD21 as a parameter of B cell activation. Clin Exp Immunol 93:195–199PubMed Huemer HP, Larcher C, Prodinger WM, Petzer AL, Mitterer M, Falser N (1993) Determination of soluble CD21 as a parameter of B cell activation. Clin Exp Immunol 93:195–199PubMed
4.
go back to reference Masilamani M, Kassahn D, Mikkat S, Glocker M, Illges H (2003) B cell activation leads to shedding of complement receptor type II (CR2/CD21). Eur J Immunol 33:2382–2390CrossRef Masilamani M, Kassahn D, Mikkat S, Glocker M, Illges H (2003) B cell activation leads to shedding of complement receptor type II (CR2/CD21). Eur J Immunol 33:2382–2390CrossRef
5.
go back to reference Ostensen M, Villiger PM (2002) Immunology of pregnancy-pregnancy as a remission inducing agent in rheumatoid arthritis. Transpl Immunol 9:155–160PubMedCrossRef Ostensen M, Villiger PM (2002) Immunology of pregnancy-pregnancy as a remission inducing agent in rheumatoid arthritis. Transpl Immunol 9:155–160PubMedCrossRef
6.
go back to reference Ostensen M, von Esebeck M, Villiger PM (2007) Therapy with immunosuppressive drugs and biological agents and use of contraception in patients with rheumatic disease. J Rheumatol 34:1266–1269PubMed Ostensen M, von Esebeck M, Villiger PM (2007) Therapy with immunosuppressive drugs and biological agents and use of contraception in patients with rheumatic disease. J Rheumatol 34:1266–1269PubMed
7.
go back to reference Tedder TF, Clement LT, Cooper MD (1984) Expression of C3d receptors during human B cell differentiation: immunofluorescence analysis with the HB–5 monoclonal antibody. J Immunol 133:678–683PubMed Tedder TF, Clement LT, Cooper MD (1984) Expression of C3d receptors during human B cell differentiation: immunofluorescence analysis with the HB–5 monoclonal antibody. J Immunol 133:678–683PubMed
8.
go back to reference Schwab J, Illges H (2001) Regulation of CD21 expression by DNA methylation and histone deacetylation. Int Immunol 13:705–710PubMedCrossRef Schwab J, Illges H (2001) Regulation of CD21 expression by DNA methylation and histone deacetylation. Int Immunol 13:705–710PubMedCrossRef
9.
go back to reference Fischer E, Delibrias C, Kazatchkine MD (1991) Expression of CR2 (the C3dg/EBV receptor, CD21) on normal human peripheral blood T lymphocytes. J Immunol 146:865–869PubMed Fischer E, Delibrias C, Kazatchkine MD (1991) Expression of CR2 (the C3dg/EBV receptor, CD21) on normal human peripheral blood T lymphocytes. J Immunol 146:865–869PubMed
10.
go back to reference Masilamani M, von Seydlitz E, Bastmeyer M, Illges H (2002) T cell activation induced by cross-linking CD3 and CD28 leads to silencing of Epstein-Barr virus/C3d receptor (CR2/CD21) gene and protein expression. Immunobiology 206:528–536PubMedCrossRef Masilamani M, von Seydlitz E, Bastmeyer M, Illges H (2002) T cell activation induced by cross-linking CD3 and CD28 leads to silencing of Epstein-Barr virus/C3d receptor (CR2/CD21) gene and protein expression. Immunobiology 206:528–536PubMedCrossRef
11.
go back to reference Larcher C, Schulz TF, Hofbauer J, Hengster P, Romani N, Wachter H, Dierich MP (1990) Expression of the C3d/EBV receptor and of other cell membrane surface markers is altered upon HIV–1 infection of myeloid, T, and B cells. J Acquir Immune Defic Syndr 3:103–108PubMed Larcher C, Schulz TF, Hofbauer J, Hengster P, Romani N, Wachter H, Dierich MP (1990) Expression of the C3d/EBV receptor and of other cell membrane surface markers is altered upon HIV–1 infection of myeloid, T, and B cells. J Acquir Immune Defic Syndr 3:103–108PubMed
12.
go back to reference Delibrias CC, Fischer E, Bismuth G, Kazatchkine MD (1992) Expression, molecular association, and functions of C3 complement receptors CR1 (CD35) and CR2 (CD21) on the human T cell line HPB-ALL. J Immunol 149:768–774PubMed Delibrias CC, Fischer E, Bismuth G, Kazatchkine MD (1992) Expression, molecular association, and functions of C3 complement receptors CR1 (CD35) and CR2 (CD21) on the human T cell line HPB-ALL. J Immunol 149:768–774PubMed
13.
go back to reference Carroll MC, Prodeus AP (1998) Linkages of innate and adaptive immunity. Curr Opin Immunol 10:36–40PubMedCrossRef Carroll MC, Prodeus AP (1998) Linkages of innate and adaptive immunity. Curr Opin Immunol 10:36–40PubMedCrossRef
14.
go back to reference Lowe J, Brown B, Hardie D, Richardson P, Ling N (1989) Soluble forms of CD21 and CD23 antigens in the serum in B cell chronic lymphocytic leukaemia. Immunol Lett 20:103–109PubMedCrossRef Lowe J, Brown B, Hardie D, Richardson P, Ling N (1989) Soluble forms of CD21 and CD23 antigens in the serum in B cell chronic lymphocytic leukaemia. Immunol Lett 20:103–109PubMedCrossRef
15.
go back to reference Masilamani M, Nowack R, Witte T, Schlesier M, Warnatz K, Glocker MO, Peter HH, Illges H (2004) Reduction of soluble complement receptor 2/CD21 in systemic lupus erythomatosus and Sjogren’s syndrome but not juvenile arthritis. Scand J Immunol 60(6):625–630 Masilamani M, Nowack R, Witte T, Schlesier M, Warnatz K, Glocker MO, Peter HH, Illges H (2004) Reduction of soluble complement receptor 2/CD21 in systemic lupus erythomatosus and Sjogren’s syndrome but not juvenile arthritis. Scand J Immunol 60(6):625–630
16.
go back to reference Masilamani M, von Kempis J, Illges H (2004) Decreased levels of serum soluble complement receptor-II (CR2/CD21) in patients with rheumatoid arthritis. Rheumatology (Oxford) 43:186–190CrossRef Masilamani M, von Kempis J, Illges H (2004) Decreased levels of serum soluble complement receptor-II (CR2/CD21) in patients with rheumatoid arthritis. Rheumatology (Oxford) 43:186–190CrossRef
17.
go back to reference Masilamani M, Apell H, Illges H (2002) Purification and characterization of soluble CD21 from human plasma by affinity chromatography and density gradient centrifugation. J Immunol Methods 270:11PubMed Masilamani M, Apell H, Illges H (2002) Purification and characterization of soluble CD21 from human plasma by affinity chromatography and density gradient centrifugation. J Immunol Methods 270:11PubMed
18.
go back to reference Aichem A, Masilamani M, Illges H (2006) Redox regulation of CD21 shedding involves signaling via PKC and indicates the formation of a juxtamembrane stalk. J Cell Sci 119:2892–2902PubMedCrossRef Aichem A, Masilamani M, Illges H (2006) Redox regulation of CD21 shedding involves signaling via PKC and indicates the formation of a juxtamembrane stalk. J Cell Sci 119:2892–2902PubMedCrossRef
19.
go back to reference Qin D, Wu J, Carroll MC, Burton GF, Szakal AK, Tew JG (1998) Evidence for an important interaction between a complement-derived CD21 ligand on follicular dendritic cells and CD21 on B cells in the initiation of IgG responses. J Immunol 161:4549–4554PubMed Qin D, Wu J, Carroll MC, Burton GF, Szakal AK, Tew JG (1998) Evidence for an important interaction between a complement-derived CD21 ligand on follicular dendritic cells and CD21 on B cells in the initiation of IgG responses. J Immunol 161:4549–4554PubMed
20.
go back to reference Fremeaux-Bacchi V, Kolb JP, Rakotobe S, Kazatchkine MD, Fischer EM (1999) Functional properties of soluble CD21. Immunopharmacology 42:31–37PubMedCrossRef Fremeaux-Bacchi V, Kolb JP, Rakotobe S, Kazatchkine MD, Fischer EM (1999) Functional properties of soluble CD21. Immunopharmacology 42:31–37PubMedCrossRef
21.
go back to reference Xu C, Mao D, Holers VM, Palanca B, Cheng AM, Molina H (2000) A critical role for murine complement regulator crry in fetomaternal tolerance. Science 287:498–501PubMedCrossRef Xu C, Mao D, Holers VM, Palanca B, Cheng AM, Molina H (2000) A critical role for murine complement regulator crry in fetomaternal tolerance. Science 287:498–501PubMedCrossRef
22.
go back to reference Grottenthaler T, von Kempis J, Goldacker S, Illges H (2006) Soluble CD21 in sera and synovial fluid of arthritic patients. Rheumatol Int 26(3):240–243 Grottenthaler T, von Kempis J, Goldacker S, Illges H (2006) Soluble CD21 in sera and synovial fluid of arthritic patients. Rheumatol Int 26(3):240–243
23.
go back to reference Nicholas NS, Panayi GS, Nouri AM (1984) Human pregnancy serum inhibits interleukin–2 production. Clin Exp Immunol 58:587–595PubMed Nicholas NS, Panayi GS, Nouri AM (1984) Human pregnancy serum inhibits interleukin–2 production. Clin Exp Immunol 58:587–595PubMed
24.
go back to reference Holland D, Bretscher P, Russell AS (1984) Immunologic and inflammatory responses during pregnancy. J Clin Lab Immunol 14:177–179PubMed Holland D, Bretscher P, Russell AS (1984) Immunologic and inflammatory responses during pregnancy. J Clin Lab Immunol 14:177–179PubMed
25.
go back to reference Griffioen AW, Franklin SW, Zegers BJ, Rijkers GT (1993) Expression and functional characteristics of the complement receptor type 2 on adult and neonatal B lymphocytes. Clin Immunol Immunopathol 69:1–8PubMedCrossRef Griffioen AW, Franklin SW, Zegers BJ, Rijkers GT (1993) Expression and functional characteristics of the complement receptor type 2 on adult and neonatal B lymphocytes. Clin Immunol Immunopathol 69:1–8PubMedCrossRef
26.
go back to reference Timens W, Boes A, Rozeboom-Uiterwijk T, Poppema S (1989) Immaturity of the human splenic marginal zone in infancy. Possible contribution to the deficient infant immune response. J Immunol 143:3200–3206PubMed Timens W, Boes A, Rozeboom-Uiterwijk T, Poppema S (1989) Immaturity of the human splenic marginal zone in infancy. Possible contribution to the deficient infant immune response. J Immunol 143:3200–3206PubMed
27.
go back to reference Rijkers GT, Sanders EA, Breukels MA, Zegers BJ (1998) Infant B cell responses to polysaccharide determinants. Vaccine 16:1396–1400PubMedCrossRef Rijkers GT, Sanders EA, Breukels MA, Zegers BJ (1998) Infant B cell responses to polysaccharide determinants. Vaccine 16:1396–1400PubMedCrossRef
28.
go back to reference Pabst HF, Kreth HW (1980) Ontogeny of the immune response as a basis of childhood disease. J Pediatr 97:519–534PubMedCrossRef Pabst HF, Kreth HW (1980) Ontogeny of the immune response as a basis of childhood disease. J Pediatr 97:519–534PubMedCrossRef
29.
go back to reference Prodeus AP, Goerg S, Shen LM, Pozdnyakova OO, Chu L, Alicot EM, Goodnow CC, Carroll MC (1998) A critical role for complement in maintenance of self-tolerance. Immunity 9:721–731PubMedCrossRef Prodeus AP, Goerg S, Shen LM, Pozdnyakova OO, Chu L, Alicot EM, Goodnow CC, Carroll MC (1998) A critical role for complement in maintenance of self-tolerance. Immunity 9:721–731PubMedCrossRef
30.
go back to reference Boackle SA, Holers VM, Chen X, Szakonyi G, Karp DR, Wakeland EK, Morel L (2001) Cr2, a candidate gene in the murine Sle1c lupus susceptibility locus, encodes a dysfunctional protein. Immunity 15:775–785PubMedCrossRef Boackle SA, Holers VM, Chen X, Szakonyi G, Karp DR, Wakeland EK, Morel L (2001) Cr2, a candidate gene in the murine Sle1c lupus susceptibility locus, encodes a dysfunctional protein. Immunity 15:775–785PubMedCrossRef
31.
go back to reference Carter RH, Fearon DT (1992) CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. Science 256:105–107PubMedCrossRef Carter RH, Fearon DT (1992) CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. Science 256:105–107PubMedCrossRef
Metadata
Title
Systemic reduction of soluble complement receptor II/CD21 during pregnancy to levels reminiscent of autoimmune disease
Authors
Madhan Masilamani
Narendiran Rajasekaran
Anjana Singh
Hui-Zhi Low
Kerstin Albus
Swantje Anders
Frank Behne
Peter Eiermann
Katharina König
Clarissa Mindnich
Teodora Ribarska
Harald Illges
Publication date
01-09-2008
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 11/2008
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-008-0604-x

Other articles of this Issue 11/2008

Rheumatology International 11/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.